Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 7/20 | 0.48 |
| ▸ | MMP9 | P14780 | 6/20 | 0.48 |
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | MMP8 | P22894 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 5/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10690394 | 0.88 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL15274643 | 0.84 | ADAM17 (0.58) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL14068217 | 0.80 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL24215090 | 0.80 | MAOA (0.54) | ADAM17ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29954271 | 0.80 | MAOA (0.54) | ADAM17ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL26208705 | 0.79 | ADAM17 (0.44) | ADAM17MMP13MMP9MMP2MMP8 | |
| SCHEMBL8011907 | 0.79 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL17202384 | 0.77 | KMT2A (0.58) | ADAM17ALDH1A1SMN1; SMN2MAPTMMP13 | |
| SCHEMBL17202385 | 0.77 | KMT2A (0.58) | ADAM17ALDH1A1SMN1; SMN2MAPTMMP13 | |
| SCHEMBL2263155 | 0.77 | RAB9A (0.47) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3134401-B1 | ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2018-06-13 | — | — | EP | disclosed |
| EP-3134401-B1 | ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2018-06-13 | — | — | EP | disclosed |
| US-9873879-B2 | Nucleic acid fragment binding to target protein | TAGCYX BIOTECHNOLOGIES (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9718792-B2 | Isoxazoline hydroxamic acid derivatives as LpxC inhibitors | NOVARTIS AG (CH) | 2017-08-01 | — | — | US | disclosed |
| US-9718792-B2 | Isoxazoline hydroxamic acid derivatives as LpxC inhibitors | NOVARTIS AG (CH) | 2017-08-01 | — | — | US | disclosed |
| US-9718792-B2 | Isoxazoline hydroxamic acid derivatives as LpxC inhibitors | NOVARTIS AG (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20170174640-A1 | ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174640-A1 | ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174640-A1 | ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-22 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | ADAM17 27/4885ALDH1A1 839/4885SMN1; SMN2 3011/4885 |
| US-20170174640-A1 | ISOXAZOLINE HYDROXAMIC ACID DERIVATIVES AS LpxC INHIBITORS | PRXL2A, AGXT, HAX1 | ADAM17 357/4885ALDH1A1 2361/4885SMN1; SMN2 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.